Previous studies have suggested that antifibrotic treatments, such as the TGF-β blocker suramin, which prevents muscle fibrosis in mdx mice, show promise in preventing DMD-related disease progression (54–56). The gene discussed is TGFB1; the disease is Duchenne muscular dystrophy.